In premenopausal women with menstrual cycle-related IBS, symptom or sign scores differed significantly between leuprolide plus placebo tablets and placebo injection plus placebo tablets.
In plain wordsWomen with menstrual cycle-related IBS who got leuprolide plus placebo tablets had different bowel symptom scores than those who got placebo.
- Peptide
- Leuprolide
- Outcome
- Direction not reportedIBS symptoms or signs
- Study
n: not reported in source
- Comparator
- Placebo injection plus placebo tablets
- Outcome group
- Gastrointestinal protection · Gastrointestinal
- Studied dose
- 11.25 mg every 3 months · intramuscular · 6 monthsAs given in this study (human).
Source sentences
A significant difference was observed between group C and groups A and B.
5 context sentences(design, population, supporting numbers)
In all groups, the mean scores for each symptom or sign of IBS and for QoL were significantly improved after treatment.
Prospective, randomized, placebo-controlled clinical trial.
One hundred twenty young premenopausal women with menstrual cycle-related IBS (Rome II criteria).
Administration of leuprolide acetate depot (LAD, 11.25 mg IM/3 months) plus tibolone (group A), LAD plus placebo tablets (group B), and injection of a placebo solution plus placebo tablets (group C).
Severity of bowel symptoms or signs of IBS and quality of life (QoL), at baseline and after 6 months of treatment.